Grupa NEUCA Company Profile

Background

Grupa NEUCA is a leading Polish healthcare company with over 30 years of experience, specializing in pharmaceutical distribution, manufacturing, medical care, clinical research, insurance, and logistics. The company aims to enhance the quality of healthcare services, products, and solutions across all its sectors. Its mission is to connect the needs of pharmacists, manufacturers, and patients, positioning itself as a pivotal player in Poland's healthcare landscape. Grupa NEUCA's vision is to be a comprehensive provider of healthcare services, offering a wide range of products and services to meet diverse patient needs.

Key Strategic Focus

Grupa NEUCA's strategic focus encompasses several core objectives:

Comprehensive Healthcare Services: Providing a broad spectrum of services, including medical care through Świat Zdrowia medical centers, health insurance, and clinical research.

Pharmaceutical Distribution and Manufacturing: Leading the distribution of pharmaceuticals in Poland and manufacturing high-quality prescription drugs, dietary supplements, and dermocosmetics.

Clinical Research: Enhancing access to innovative therapies by creating a cohesive data stream between patients, researchers, and research centers.

Technological Integration: Leveraging advanced IT tools and data management to improve healthcare delivery and operational efficiency.

The company utilizes technologies such as Azure DevOps, GitLab, and Django to support its operations.

Financials and Funding

Grupa NEUCA has demonstrated consistent financial growth:

2024 Performance: Achieved sales revenues of PLN 12.6 billion, marking a 6.8% year-on-year increase. The EBITDA stood at PLN 394.9 million, a 4% increase from the previous year, and the net profit exceeded PLN 170 million, reflecting a 7.6% year-on-year growth.

Dividend Distribution: In 2024, the company paid a dividend of PLN 14.5 per share, totaling PLN 64.8 million. For 2025, the Board of Directors recommended a dividend of PLN 16 per share.

Investment: In September 2024, Grupa NEUCA's subsidiary, Humaneva Inc., secured a USD 50 million investment from Viking Global Investors, with an additional one-year option for USD 50 million. This investment aims to bolster the company's clinical trials division.

Pipeline Development

Grupa NEUCA is actively involved in clinical research, focusing on:

Clinical Trials: Conducting a significant number of clinical trials, enhancing access to innovative therapies.

Research Centers: Operating one of the largest independent networks of clinical trial centers in Europe.

Technological Platform and Innovation

The company distinguishes itself through:

Proprietary Technologies: Developing and utilizing advanced IT tools to streamline operations and improve service delivery.

Scientific Methods: Implementing innovative approaches in clinical research to facilitate the development of new therapies.

AI-Driven Capabilities: Integrating artificial intelligence to enhance data analysis and decision-making processes.

Leadership Team

As of February 2026, the leadership team includes:

Grzegorz Dzik: Chief Executive Officer (CEO) since August 2010, responsible for overall strategic direction and operations.

Radosław Dzik: Vice President & Chief Information Officer (CIO), overseeing the company's IT strategy and infrastructure.

Remigiusz Kinas: Head of Artificial Intelligence, leading AI initiatives within the company.

Krzysztof Mikołajczak: Head of Communication with the Medical Sector, managing relationships and communications with healthcare professionals.

Marek Górski: Head of Sales (Independent Pharmacy Market), responsible for sales strategies targeting independent pharmacies.

Tomasz Dąbrowski: CEO of Humaneva Group, focusing on clinical trials and research operations.

Leadership Changes

In December 2025, Piotr Sucharski resigned from his position as a Board Member of NEUCA S.A., effective December 31, 2025, and expressed his intention to run for the Supervisory Board. The Supervisory Board of NEUCA S.A. resolved to appoint Grzegorz Dzik as the CEO of NEUCA S.A., effective January 1, 2026.

Market Insights and Competitor Profile

The Polish pharmaceutical market has experienced steady growth, with the pharmacy wholesale market valued at PLN 12.6 billion in the first quarter of 2025, an 8.6% year-on-year increase.

Grupa NEUCA's primary competitors include:

Pelion S.A.: A significant player in pharmaceutical distribution and retail in Poland.

Farmacol S.A.: Engaged in wholesale distribution and retail of pharmaceutical products.

Polpharma S.A.: A leading pharmaceutical manufacturer with a strong presence in the Polish market.

These competitors focus on pharmaceutical distribution, manufacturing, and retail, with varying degrees of involvement in clinical research and healthcare services.

Strategic Collaborations and Partnerships

Grupa NEUCA has established several strategic collaborations:

Viking Global Investors: In September 2024, secured a USD 50 million investment in Humaneva Inc., a subsidiary specializing in clinical trials.

Herbapol Poznań S.A.: A 35-year partnership focusing on joint business planning, preventive health projects, and patient care initiatives.

Teva Pharmaceuticals Polska: Collaborated to improve the availability of a specific medication through joint business planning, enhancing distribution and accessibility.

Operational Insights

Grupa NEUCA maintains a strong market position with a 29.5% share in the pharmacy wholesale market and a 37.6% share in the independent pharmacy segment as of the first quarter of 2025. The company's diversified portfolio, encompassing pharmaceutical distribution, manufacturing, medical services, and clinical research, provides a competitive edge in the healthcare sector.

Strategic Opportunities and Future Directions

Grupa NEUCA is well-positioned to leverage its comprehensive service offerings and strategic partnerships to:

Expand Clinical Research: Enhance the scope and impact of clinical trials through increased investment and collaboration.

Integrate Advanced Technologies: Further incorporate AI and data analytics to optimize operations and patient care.

Strengthen Market Presence: Increase market share in both wholesale distribution and independent pharmacy segments.

Enhance Customer Satisfaction: Maintain high levels of customer trust and satisfaction, as evidenced by a Net Promoter Score of 70 points in 2024.